Targeted therapies for myeloproliferative neoplasms

Targeted therapies for myeloproliferative neoplasms

Abstract The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivota...

Full description

Bibliographic Details
Main Authors: Bing Li, Raajit K. Rampal, Zhijian Xiao
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Biomarker Research
Subjects:
Targeting therapy
Myeloproliferative neoplasms
Online Access:http://link.springer.com/article/10.1186/s40364-019-0166-y

Internet

http://link.springer.com/article/10.1186/s40364-019-0166-y

Similar Items